Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity

BACKGROUND: We previously reported preliminary results of our phase I study of continuous daily sorafenib with bevacizumab every other week for solid tumours. Toxicity was moderate, leading to additional dose levels (DL) testing intermittent sorafenib dosing. METHODS: Seventeen patients with advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, J-M, Sarosy, G A, Annunziata, C M, Azad, N, Minasian, L, Kotz, H, Squires, J, Houston, N, Kohn, E C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822947/
https://www.ncbi.nlm.nih.gov/pubmed/20051952
http://dx.doi.org/10.1038/sj.bjc.6605514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822947/
https://www.ncbi.nlm.nih.gov/pubmed/20051952
http://dx.doi.org/10.1038/sj.bjc.6605514

Ejemplares similares